Did an FDA Panel Really Just Approve the First Gene Therapy Treatment? This week marked a major milestone in medicine: On Wednesday, a Food and Drug Administration panel unanimously recommended the approval of the first CAR- T therapy, a pioneering new cancer drug from Novartis that genetically engineers a patient’s own white blood cells to recognize and attack the cancer cells invading their body. The headlines were emphatic.
And then, in true internet- era fashion, came the pedantry: In a world in which being “first” can mean clickier headlines, more traction and eventually even more research dollars, it’s a label that matters. It is clear that the drug—the practically unpronounceable tisagenlecleucel—is a landmark achievement. CAR- T therapy, which several other companies are also pursuing drugs for, works by extracting and isolating a patient’s T cells, genetically altering them, and then infusing them back into the patient’s body. In one key clinical trial, 8. CAR- T infusion. After one year, 7. It’s less clear, what, exactly, Novartis’ groundbreaking drug may have been the first of. The FDA, for one, defines human gene therapy vaguely as “products that introduce genetic material into a person’s DNA to replace faulty or missing genetic material, thus treating a disease or abnormal medical condition.”The agency notes that, so far, no such product has been approved for sale in the US.
On Twitter, scientists and reporters argued about whether that definition of gene therapy meant the gene itself must be the treatment—if so, CAR- T would not qualify, as it is the souped- up white blood cells that are the treatment, rather than the genes that have been added to them. The edits made do not directly correct a biological defect. Gene therapies, this camp might argue, require more editing, and CAR- T is simply a cell therapy. Others argued that anything involving genetic alteration qualified as gene therapy, which might make CAR- T the first. The agency does not have to follow that recommendation, but it typically does.
It is expected to make a decision in September. Upon approval, Novartis has said it plans a slow roll- out because of serious side effects that result from the therapy, mainly making it available to only a few dozen medical establishments.
Serial correlation is the relationship between a given variable and itself over various time intervals. Serial correlations are often found in repeating patterns.
- Panel Data Models with Heterogeneity and Endogeneity Jeff Wooldridge Michigan State University Programme Evaluation for Policy Analysis Institute for Fiscal Studies.
- Longitudinal and Panel Data: Analysis and Applications for the Social Sciences Brief Table of Contents Chapter 1. Introduction PART I - LINEAR MODELS.
The FDA’s pending decision could have big implications for other companies developing similar treatments, such as Kite Pharma and Juno Therapeutics. Download Game Java 240X320 Nokia 6300. And big implications for patients, whether we settle on calling it gene therapy or not.